Sat, January 18, 2025
Fri, January 17, 2025
Thu, January 16, 2025
[ Thu, Jan 16th ]: MSN
Opening Bell: 1.15.25
Wed, January 15, 2025
Tue, January 14, 2025
Mon, January 13, 2025
[ Mon, Jan 13th ]: CNET
Rocket Money Review 2025
[ Mon, Jan 13th ]: CFO
A CFO action plan for 2025
Sun, January 12, 2025
Sat, January 11, 2025
Fri, January 10, 2025
Thu, January 9, 2025

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

  Copy link into your clipboard //business-finance.news-articles.net/content/202 .. grapples-with-uncertainty-over-trump-return.html
  Print publication without navigation Published in Business and Finance on by Reuters
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities might be on hot button issues such as drug pricing reforms and vaccines.

- Click to Lock Slider
The biopharmaceutical industry is anticipating a potential recovery in 2025 following a challenging period marked by economic pressures, patent expirations, and regulatory uncertainties. According to a Reuters report, industry leaders are cautiously optimistic about a rebound, driven by the expected launch of new drugs and the potential for increased M&A activity. However, the sector faces significant uncertainty due to the possibility of Donald Trump's return to the presidency, which could lead to policy changes affecting drug pricing, international trade, and healthcare regulations. Trump's previous term saw initiatives like the "most favored nation" pricing model, which aimed to lower drug costs by aligning U.S. prices with those in other countries, causing concern among biopharma companies about future profitability and innovation incentives. Additionally, the industry is grappling with the ongoing effects of the Inflation Reduction Act, which allows Medicare to negotiate drug prices, further complicating the financial landscape for biopharma companies.

Read the Full Reuters Article at:
[ https://www.reuters.com/business/healthcare-pharmaceuticals/biopharma-industry-eyes-2025-bounceback-grapples-with-uncertainty-over-trump-2025-01-14/ ]


Similar Business and Finance Publications